Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
“Today, after over a year of steadfast transformation and execution, Entera stands as a premier oral peptide company.
- “Today, after over a year of steadfast transformation and execution, Entera stands as a premier oral peptide company.
- We are also exploring the potential use of EB613 to accelerate stress fracture healing due to high intensity athletic or military training.
- Entera Q3 2023 Updates and Goals for 5 Oral Peptide Programs:
EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis. - Entera published pre-clinical data in May 2023 demonstrating that its oral peptide delivery platform enables gastric absorption of teduglutide, as a convenient potential tablet alternative to daily injections.